BERLIN (GERMANY) -German biotech firm CureVac has set out with the first participant for its COVID-19 vaccine candidate’s Phase 2b/3 clinical trial, it said on Monday.
The trial, which is relevant for regulatory approval, will evaluate whether it is safe and efficient enough on adults. It added that it is likely to enroll more than 35,000 participants in Europe and Latin America, it added in a statement.
CureVac said that the study aims to bring out the efficacy of its vaccine candidate.
Chief Executive Franz-Werner Haas said, “The clinical safety and immunogenicity data achieved to date look promising and we are hopeful that this trial will continue to demonstrate the impact of mRNA technology and our vaccine to prevent COVID-19, and to help defeat this pandemic.”
CureVac’s vaccine candidate is among the three German vaccine projects that the German government is extending its support with about 750 million euros ($911 million) in total.
